Companies › Shanghai Ming Ju Biotechnology
2 active drug programs in 7 registered trials: 5 Phase 2, 1 Phase 4, 1 Phase 1; Oncology, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Relma-cel CD19-targeted CAR T cells | CD19 | Phase 2 | Non-Hodgkin Lymphoma; Relapsed or Refractory B-cell Lymphoma; B-cell Non Hodgkin Lymphoma; CNS Lymphoma … | Dec 2026 |
| Relmacabtagene Autoleucel (JWCAR029) CAR-T cell therapy targeting CD19 | CD19 | Phase 2 | Mantle Cell Lymphoma; Lymphoma, Large B-Cell, Diffuse | Aug 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06479356 | Relma-cel | Phase 2 | Non-Hodgkin Lymphoma | Oncology | Dec 2026 |
| NCT06365671 | Relma-cel | Phase 2 | B-cell Non Hodgkin Lymphoma | Oncology | Apr 2027 |
| NCT06414135 | Relma-cel | Phase 1 | Systemic Sclerosis | Immunology | Apr 2027 |
| NCT05806580 | Relma-cel | Phase 4 | Relapsed or Refractory B-cell Lymphoma | Oncology | May 2027 |
| NCT04718883 | Relmacabtagene Autoleucel (JWCAR029) | Phase 2 | Mantle Cell Lymphoma | Oncology | Aug 2028 |
| NCT06876688 | Relma-cel | Phase 2 | CNS Lymphoma | Oncology | Nov 2028 |
| NCT06093841 | Relmacabtagene Autoleucel (JWCAR029) | Phase 2 | Lymphoma, Large B-Cell, Diffuse | Oncology | Nov 2029 |
Beijing Yongtai Ruike Biotechnology Company Autolus ADC Therapeutics Juventas Cell Therapy Fate Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.